French AML study tracks Real-World outcomes on maintenance drug
NCT ID NCT06565975
First seen Feb 18, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This completed study gathered real-world information from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. Researchers tracked how long patients stayed relapse-free, overall survival, and treatment patterns. The goal was to understand patient characteristics and outcomes outside of a controlled trial setting, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kappa Sante
Paris, 75002, France
Conditions
Explore the condition pages connected to this study.